GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

8 hours ago
R&D

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

10 hours ago
Deals
R&D

Mer­ck shut­ters French re­search site in a re­or­ga­ni­za­tion aimed at elim­i­nat­ing more than 200 jobs

Yesterday
Pharma

Cel­gene ex­ecs shell out $92M cash for a pair of R&D deals that will fit per­fect­ly in their new home at Bris­tol-My­ers

Yesterday
R&D

FDA Vas­cepa re­view spot­lights new safe­ty sig­nals, pos­si­ble min­er­al oil spoil­er as Amarin hunts a block­buster ap­proval

Yesterday
R&D

Kad­mon wax­es rhap­sod­ic on cGVHD re­sults as race with Jakafi heats up

Yesterday
R&D

FDA puts Sol­id Bio’s lead gene ther­a­py pro­gram on hold — again — af­ter an­oth­er pa­tient is hurt by SGT-001

Yesterday
Cell/Gene Tx
R&D

The lat­est Cin­derel­la sto­ry in on­col­o­gy ends with a sud­den rout as up­dat­ed da­ta dis­play spooks in­vestors

2 days ago
R&D

Roche's SMA chal­lenge to Bio­gen's Spin­raza fran­chise looms larg­er with piv­otal win

2 days ago
R&D

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

2 days ago
People
R&D

UP­DAT­ED: As­traZeneca, Fi­bro­Gen flag ap­peal­ing pooled safe­ty da­ta on roxa for key seg­ment of the CKD mar­ket

5 days ago
R&D

An­ces­tryD­NA chief takes on liq­uid biop­sy chal­lenge; Thomas Lynch chairs for­mer col­league's can­cer start­up

5 days ago
Peer Review

Anap­tys­Bio gives in­vestors a rash as its big bet on eczema fails, sink­ing stock

5 days ago
R&D

Fol­low­ing a win for Baven­cio, Pfiz­er and Mer­ck KGaA con­tin­ue PD-L1 los­ing streak

5 days ago
Pharma
R&D

Monopar de­lays IPO again de­spite slash­ing of­fer­ing while a mi­cro-cap biotech clinch­es $9M

5 days ago
IPOs

Tri­fec­ta of in­com­ing mi­graine meds must be cheap­er than trip­tans to be cost-ef­fec­tive — ICER

5 days ago
Pharma

Roche aban­dons an­ti-myo­statin ap­proach to Duchenne MD — one more nail in the class' cof­fin

6 days ago
R&D

Some bat­tle test­ed neu­ro­science vets are go­ing all out on ear­ly on­set de­men­tia — with a $44M launch round to build the team

6 days ago
R&D
Startups

HHS is tak­ing Gilead to court, seek­ing dam­ages for in­fring­ing gov­ern­ment HIV patents

6 days ago
Pharma
Regulatory

Re­genxBio runs in­to par­tial hold for an­ti-VEGF gene ther­a­py as FDA in­ves­ti­gates de­liv­ery de­vice

6 days ago
Cell/Gene Tx
Regulatory

George Church start­up eGe­n­e­sis rakes $100M to ramp up CRISPR pig or­gan trans­plants

6 days ago
Venture

As­traZeneca sketch­es plans for a $1B ven­ture fund — and it's go­ing to Chi­na

Last week
China
Venture

On the heels of a $6.9B As­traZeneca pact, IP dis­pute be­tween Dai­ichi Sankyo and Seat­tle Ge­net­ics rips open in law­suit

Last week
Pharma
R&D

An­oth­er ex-Shire re­search ex­ec heads out, grab­bing top R&D job at deal-hun­gry Ipsen as post-buy­out ex­o­dus con­tin­ues

Last week
People
R&D
1234 Next page Last page